Literature DB >> 1739521

Antiarrhythmic drug treatment: need for continuous vigilance.

H J Wellens1, J L Smeets, M Vos, A P Gorgels.   

Abstract

Any physician treating cardiac arrhythmias should be aware of a possible worsening of the arrhythmia (so-called arrhythmogenesis) after the start of antiarrhythmic drug treatment. To facilitate the recognition of that complication the type and possible mechanisms of arrhythmogenesis are reviewed. Recognition also requires an understanding of (a) the time of appearance of arrhythmogenic effects after different drugs, (b) the value of non-invasive and invasive tests, and (c) the profile of the patient most likely to develop this problem. Guidelines are given to reduce the incidence of the arrhythmogenic effects of antiarrhythmic drugs and a plea is made that the physician should be always on the alert for this complication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1739521      PMCID: PMC1024695          DOI: 10.1136/hrt.67.1.25

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  21 in total

Review 1.  Cardiac electrophysiology: promises and contributions.

Authors:  D P Zipes
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

2.  Torsade De Pointes, an atypical ventricular tachycardia.

Authors:  D M Krikler; P V Curry
Journal:  Br Heart J       Date:  1976-02

3.  Arrhythmogenesis of antiarrhythmic drugs.

Authors:  P Brugada; H J Wellens
Journal:  Am J Cardiol       Date:  1988-05-01       Impact factor: 2.778

4.  Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy.

Authors:  J D Minardo; J J Heger; W M Miles; D P Zipes; E N Prystowsky
Journal:  N Engl J Med       Date:  1988-08-04       Impact factor: 91.245

5.  Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment.

Authors:  H J Crijns; I C van Gelder; K I Lie
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

6.  Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.

Authors:  S Ranger; M Talajic; R Lemery; D Roy; S Nattel
Journal:  Circulation       Date:  1989-05       Impact factor: 29.690

7.  Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval.

Authors:  P T Nguyen; M M Scheinman; J Seger
Journal:  Circulation       Date:  1986-08       Impact factor: 29.690

8.  Silent myocardial ischemia during daily activities in asymptomatic men with positive exercise test responses.

Authors:  K M Coy; G A Imperi; C R Lambert; C J Pepine
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

Review 9.  Treatment of cardiac arrhythmias: when, how and where?

Authors:  H J Wellens; P Brugada
Journal:  J Am Coll Cardiol       Date:  1989-11-15       Impact factor: 24.094

10.  Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.

Authors:  P K Au; A K Bhandari; R Bream; D Schreck; R Siddiqi; S H Rahimtoola
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.